Latest Conference Articles

First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.

Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.

Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Elisrasib produced a 58.8% ORR and 12.2-month median PFS in KRAS G12C inhibitor–naive NSCLC and remained active in G12C inhibitor–refractory disease.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

Lena Specht, MD, DMSc, discusses data for mogamulizumab in Danish patients with mycosis fungoides or Sezary syndrome and their effect on clinical practice.

Robert Stuver, MD, discusses how to approach treatment for primary cutaneous peripheral T-cell lymphoma and which factors to consider.

H. Miles Prince, MD, MBBS discusses data for mogamulizumab from MAVORIC vs real-world vorinostat in R/R MF and SS.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Neha Mehta-Shah, MD, MSCI explains how rational combinations to overcome CTCL treatment resistance keep running into added toxicity.

Real-world treatment with pegylated interferon alfa-2a tolerable, and treatment-related AEs were manageable in patients with cutaneous T-cell lymphoma.

Julia Scarisbrick, MD, explains how better recognition of mogamulizumab-associated rash is moving the drug earlier in the mycosis fungoides and Sézary treatment course.

Julia Scarisbrick reviews real-world data showing mogamulizumab eased itch, pain, flaking, sleep, and fatigue in MF and Sézary syndrome as early as 4 weeks.

Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.

In a phase 1 trial, duvelisib plus nivolumab produced a 26% overall response rate in relapsed/refractory cutaneous T-cell lymphoma but was limited by immune-mediated toxicities.

Real-world mogamulizumab reduced skin symptoms and improved health-related quality of life in patients with mycosis fungoides and Sézary syndrome.

Dibotatug was deemed tolerable and produced robust responses across subgroups of patients with relapsed/refractory cytotoxic T/NK cell lymphomas.

Christiane Querfeld, MD, PhD, discusses why early symptom relief drives adherence in mycosis fungoides and Sézary syndrome, and reframing MAR as an immune flare helps patients stay the course.

Christiane Querfeld, MD, PhD, discusses how targeted sequencing data show Sézary syndrome responds to mogamulizumab better than mycosis fungoides.

Jan P. Nicolay, MD, PhD, explains how early single-cell data suggest mogamulizumab resistance switches on anti-apoptotic survival proteins.

Jan P. Nicolay, MD, PhD, explains why some patients stop responding to mogamulizumab comes down to the tumor shedding its target and new survival mechanisms the cell switches on.

Two cutaneous lymphoma experts — Michael Girardi, MD, and Joan Guitart, MD — stake out opposite answers to whether SPTCL is truly a lymphoma.

BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.

The final analysis of the Italian FIL-MOGA study showed an objective response lasting at least 4 months in 47% of patients and identified the measure as a surrogate for survival outcomes.

In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.

A rare cutaneous lymphoma that can mimic lupus and melt away on steroids still belongs in the malignancy category, based on how it behaves off treatment.

In part 2, the debaters map the trial that could settle the question and agree that, for now, individualized care and closer monitoring should guide high-risk early MF.

Stopping mogamulizumab after a strong response — then resuming it at relapse — emerged as a viable strategy for select patients with Sézary syndrome.

In the beginning of a two-part debate, two experts agree the evidence to treat poor-prognosis early MF differently from the onset isn’t here yet.